Humane Genomics is at the forefront of cancer treatment innovation, utilizing synthetic biology to engineer RNA viruses specifically designed to target and kill cancer cells. Their advanced platform streamlines the design and testing of oncolytic viral therapies, allowing for the creation of complex viral structures through a computer-aided design process. This technology enables the reuse of established building blocks, ensuring high-quality DNA synthesis that is crucial for assembling complete viral genomes. The company emphasizes the importance of safety and efficacy in their therapies, which are characterized by selective infection and replication, leading to highly lytic actions that efficiently eliminate cancer cells.

The therapeutic products developed by Humane Genomics are designed to maximize treatment effectiveness while minimizing adverse effects. Their oncolytic viruses are engineered to have a prolonged therapeutic duration without triggering significant immune responses, allowing for systematic delivery to both primary tumors and metastases. Additionally, the company focuses on cost-effective production methods, ensuring that their innovative therapies can be manufactured efficiently. Overall, Humane Genomics is committed to revolutionizing cancer treatment through precision-engineered viral therapies that prioritize patient safety and treatment efficacy.

United States

Humane Genomics is developing a platform to engineer cancer killing viruses with unprecedented specificity and efficiency. Our first indication is liver cancer. We are based in New York City and backed by amazing investors. (YC S21)

Humane Genomics

Company Details